Medicolegal Implications of SABA Therapy in Asthma Management Webinar

March 9 at 7.30 pm EST

SABA overreliance is correlated with a higher risk of exacerbations and mortality. It is underappreciated as being correlated with poor asthma outcomes. We have taught and will continue to teach the science, but educating on both the positive patient benefits associated with solving their over reliance on SABAs, and the potential medical and medico-legal risks will help you make better-informed clinical decisions. This program will review the science and explain the medicolegal risk of prescribing SABAs alone for asthma management.


Join Dr. Alan Kaplan MD CCFP(EM) FCFP, & Marc Koplowitz LLB, Juris Doctor, as they discuss the following learning objectives:

  • Understand the use of SABAs in practice
  • Recognize the limitations of SABAs in the management of Asthma
  • Recognize current recommendations in Asthma management
  • Assess the medicolegal risks of continuing to use SABAs in Asthma management

This webinar is sponsored and created with an unrestricted grant from Astra Zeneca.

*To receive the webinar link, please register prior to the webinar.

March 9th, 2021 at 7:30 pm EST 
Estimated length: 1 hour 15 minutes